Portal de Periódicos da CAPES

Prognostic Impact of let-7e MicroRNA and Its Target Genes in Localized High-Risk Intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study

2020; Multidisciplinary Digital Publishing Institute; Volume: 12; Issue: 10 Linguagem: Inglês

10.3390/cancers12102979

2072-6694

Antonio Fernández‐Serra, David S. Moura, María Dolores Sanchez-Izquierdo, Sílvia Calabuig-Fariñas, María López-Álvarez, Andrea Martínez-Martínez, Irene Carrasco-García, Marta Ramírez-Calvo, Elena Blanco‐Alcaina, R. Fernández López, Antònia Obrador‐Hevia, Regina Alemany, Antonio Gutiérrez, Nadia Hindi, Andrés Poveda, José Antonio López‐Guerrero, Javier Martín‐Broto,

Metastasis and carcinoma case studies

MicroRNAs (miRNAs) are small non-coding RNAs that negatively regulate gene expression at the post-transcriptional level, and they have been described as being associated with tumor prognosis. Here, miRNA profiling was planned to explore new molecular prognostic biomarkers in localized intestinal high-risk GIST. Paraffin tumor blocks of 14 and 86 patients were used in the discovery and expansion sets, respectively. GeneChip miRNA v3.0 was employed to identify the miRNAs differentially expressed between relapsed and non-relapsed patient samples, which were validated in the expansion set, by qRT-PCR. RT2 Profiler PCR Array was used for the screening of let-7e targets. Expression levels were correlated with relapse-free survival and overall survival. In the discovery set, 39 miRNAs were significantly deregulated, let-7e and miR-550 being the most underexpressed and overexpressed miRNAs in the relapsed group, respectively. In the expansion set, the underexpression of let-7e or the overexpression of 4 of its target genes (ACVR1B, CASP3, COL3A1, and COL5A2) were statistically associated with worse relapse-free survival. The expression of let-7e and 4 of its target genes are potential prognostic biomarkers in high-risk localized intestinal GIST. The expression of these genes is a potential molecular tool useful for a more accurate prognosis in this subset of GIST patients.